Suppr超能文献

术前D-二聚体与白蛋白比值对结直肠癌总生存期和无进展生存期的预后价值。

The prognostic value of preoperative D-dimer to albumin ratio for overall survival and progression-free survival in colorectal cancer.

作者信息

Wei Lishuang, Xie Hailun, Wang Qiwen, Tang Shuangyi, Gan Jialiang

机构信息

Department of Colorectal and Anal Surgery, The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, China.

Guangxi Key Laboratory of Enhanced Recovery After Surgery for Gastrointestinal Cancer, Nanning, Guangxi, China.

出版信息

Front Physiol. 2024 Feb 29;15:1369855. doi: 10.3389/fphys.2024.1369855. eCollection 2024.

Abstract

This study aimed to explore the predictive value of the D-dimer-to-albumin ratio (DAR) for progression-free survival (PFS) and overall survival (OS) in patients with colorectal cancer (CRC). The Kaplan-Meier method was used to plot survival curves for PFS and OS. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive efficacy of the DAR for PFS and OS in patients with CRC. Cox proportional hazards regression analysis was used to analyze prognostic factors influencing outcomes. A nomogram based on the DAR was constructed to predict 1-, 3-, and 5-year prognoses of patients with CRC; its predictive ability was evaluated using the concordance index (C-index) and calibration curves. Additionally, the clinical utility of the DAR-based nomogram was validated using an internal randomized validation cohort. A total of 1,339 patients with CRC who underwent surgery were enrolled. The optimal cut-off value for DAR was determined to be 3.320, dividing patients into low (<3.320 [n = 470]) and high (≥3.320 [n = 869]) DAR groups. Compared with other composite immune inflammatory markers, DAR exhibited superior prognostic predictive efficacy. Patients with a high DAR had a significantly worse prognosis than those with a low DAR (PFS, 50.9% [vs.] 69.4%, < 0.001; OS, 52.9% vs. 73.8%, < 0.001). DAR also demonstrated significant prognostic stratification for most tumor subgroups, particularly in the stage III-IV subgroup and normal carcinoembryonic antigen subgroup. DAR has been identified as an independent predictive indicator of PFS/OS in patients with CRC. For every standard deviation increase in DAR, the risk for PFS/OS in patients with CRC was reduced by 9.5% (hazard ratio [HR] 1.095 [95% confidence interval (CI) 1.013-1.185]; = 0.022) and 9.3% (HR 1.093 [95% CI 1.012-1.180]; = 0.024), respectively. The DAR-based nomogram was confirmed to demonstrate good prognostic prediction accuracy and achieved high evaluation in the internal validation cohort. Preoperative DAR is a promising biomarker for predicting PFS and OS among patients with CRC. The DAR-based prognostic prediction nomogram may serve as an effective tool for the comprehensive assessment of prognosis in patients with CRC.

摘要

本研究旨在探讨D-二聚体与白蛋白比值(DAR)对结直肠癌(CRC)患者无进展生存期(PFS)和总生存期(OS)的预测价值。采用Kaplan-Meier法绘制PFS和OS的生存曲线。采用受试者工作特征(ROC)曲线分析评估DAR对CRC患者PFS和OS的预测效能。采用Cox比例风险回归分析来分析影响预后的因素。构建了基于DAR的列线图以预测CRC患者1年、3年和5年的预后;使用一致性指数(C指数)和校准曲线评估其预测能力。此外,使用内部随机验证队列验证了基于DAR的列线图的临床实用性。共纳入1339例接受手术的CRC患者。确定DAR的最佳截断值为3.320,将患者分为低DAR组(<3.320 [n = 470])和高DAR组(≥3.320 [n = 869])。与其他复合免疫炎症标志物相比,DAR表现出更好的预后预测效能。高DAR患者的预后明显比低DAR患者差(PFS,50.9% [对比] 69.4%,<0.001;OS,52.9% 对比 73.8%,<0.001)。DAR在大多数肿瘤亚组中也显示出显著的预后分层,特别是在III-IV期亚组和癌胚抗原正常亚组中。DAR已被确定为CRC患者PFS/OS的独立预测指标。DAR每增加一个标准差,CRC患者PFS/OS的风险分别降低9.5%(风险比[HR] 1.095 [95%置信区间(CI)1.013 - 1.185];P = 0.022)和9.3%(HR 1.093 [95% CI 1.012 - 1.180];P = 0.024)。基于DAR的列线图被证实具有良好的预后预测准确性,并在内部验证队列中获得了高度评价。术前DAR是预测CRC患者PFS和OS的一个有前景的生物标志物。基于DAR的预后预测列线图可作为综合评估CRC患者预后的有效工具。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/228e/10937459/c16899096f5e/fphys-15-1369855-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验